ARCE THERAPEUTICS, INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83505884
Status
Active
Number of Employees
0
Total Paid-in
Capital
297,029,813 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Our Vision: Focus on the needs of patients to achieve the goals of effective treatment of diseases and reasonable medical expenses through our "innovative immune cell therapy". To make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.
Our Mission: Transform the lives of patients with unmet medical needs through pursuing science in action, conquering adversity with resilience, teamwork in collaboration, and a commitment to excellence.
ARCE Therapeutics, Inc. is a global biotech company, established in 2020 to develop patented intellectual properties in immune cell & gene engineering technology. ARCE is developing first-in-class and best-in-class CAR-T/CAR-NK cell therapy products for the treatment of various forms of cancers, including hematological cancers and solid tumors. Through ARCE’s innovative immune cell therapy and commercialization development, ARCE provides state-of-the-art products of new generation CAR-T/CAR-NK cell therapy, to make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.
Our Mission: Transform the lives of patients with unmet medical needs through pursuing science in action, conquering adversity with resilience, teamwork in collaboration, and a commitment to excellence.
ARCE Therapeutics, Inc. is a global biotech company, established in 2020 to develop patented intellectual properties in immune cell & gene engineering technology. ARCE is developing first-in-class and best-in-class CAR-T/CAR-NK cell therapy products for the treatment of various forms of cancers, including hematological cancers and solid tumors. Through ARCE’s innovative immune cell therapy and commercialization development, ARCE provides state-of-the-art products of new generation CAR-T/CAR-NK cell therapy, to make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.
The content above was translated by Ai
